公开(公告)号：US20230265101A1

公开(公告)日：2023-08-24

申请号：US18004109

申请日：2021-06-30

申请人： PFIZER INC.

发明人： Adam Edward GOETZ ,  Sally Gut RUGGERI ,  Robert Alan SINGER

IPC分类号： C07D487/08

CPC分类号： C07D487/08

摘要： Methods for preparing ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone and intermediates used in the processes of preparation thereof.

公开(公告)号：US11723965B2

公开(公告)日：2023-08-15

申请号：US17395108

申请日：2021-08-05

申请人： PFIZER INC.

发明人： Jianxin Gu ,  Jin-hwan Kim ,  Avvari Krishna Prasad ,  Yu-ying Yang

IPC分类号： A61K39/095 ,  A61K47/64 ,  A61K39/09 ,  A61K45/06 ,  A61K39/00

CPC分类号： A61K39/095 ,  A61K39/092 ,  A61K45/06 ,  A61K47/64 ,  A61K47/646 ,  A61K47/6415 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/627

摘要： The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20230235070A1

公开(公告)日：2023-07-27

申请号：US18002368

申请日：2021-06-23

申请人： Pfizer Inc.

发明人： Mary Lynn BANIECKI ,  Mina HASSAN-ZAHRAEE ,  Kenneth Eugene HUNG ,  Gang LI ,  Li XI ,  Zhan YE

IPC分类号： C07K16/28 ,  A61P1/12

CPC分类号： C07K16/2875 ,  A61P1/12

摘要： The present invention relates to a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an anti-TNF-like ligand 1A (TL1A) antibody in an induction dosing regimen sufficient to improve signs and symptoms of IBD by at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the method further comprises administering to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.

公开(公告)号：US20230233671A1

公开(公告)日：2023-07-27

申请号：US18045967

申请日：2022-10-12

申请人： Pfizer Inc.

发明人： Eric Matthew Bennett ,  Fernando Martin Diaz ,  Philip Ralph Dormitzer ,  Kathrin Ute Jansen ,  Raquel Munoz-Moreno ,  Alicia Solorzano Quijano

IPC分类号： A61K39/25 ,  A61K47/69 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

CPC分类号： A61K39/25 ,  A61K47/6929 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

摘要： The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.

公开(公告)号：US11702424B2

公开(公告)日：2023-07-18

申请号：US16996117

申请日：2020-08-18

申请人： Pfizer Inc.

发明人： John David Trzupek ,  Katherine Lin Lee ,  Mark Edward Bunnage ,  Seungil Han ,  David Hepworth ,  Frank Eldridge Lovering ,  John Paul Mathias ,  Nikolaos Papaioannou ,  Betsy Susan Pierce ,  Joseph Walter Strohbach ,  Stephen Wayne Wright ,  Christoph Wolfgang Zapf ,  Lori Krim Gavrin ,  Arthur Lee ,  David Randolph Anderson ,  Kevin Joseph Curran ,  Christoph Martin Dehnhardt ,  Eddine Saiah ,  Joel Adam Goldberg ,  Xiaolun Wang ,  Horng-Chih Huang ,  Richard Vargas ,  Michael Dennis Lowe ,  Akshay Patny

IPC分类号： C07D491/056 ,  C07F7/18 ,  C07D401/14 ,  C07D405/14 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D207/273 ,  C07D498/04 ,  C07D209/52 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  C07C69/94 ,  A61K31/541 ,  A61K45/06 ,  C07D207/26 ,  C07D215/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  A61K31/40 ,  C07D207/08 ,  C07D207/267

CPC分类号： C07D491/056 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C69/94 ,  C07D207/08 ,  C07D207/26 ,  C07D207/267 ,  C07D207/273 ,  C07D209/52 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D498/04 ,  C07F7/1804

摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,




as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20230202987A1

公开(公告)日：2023-06-29

申请号：US18170884

申请日：2023-02-17

申请人： Pfizer Inc.

发明人： Elaine GREER ,  Stephen ANDERSON ,  Mark MALONEY ,  Shu YU ,  Ekaterina ALBERT ,  Emily RIGSBEE

IPC分类号： C07D233/88

CPC分类号： C07D233/88 ,  A61K31/40 ,  C07B2200/13

摘要： The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

公开(公告)号：US20230201283A1

公开(公告)日：2023-06-29

申请号：US17790160

申请日：2021-01-05

申请人： Pfizer Inc.

发明人： Joseph John Binder ,  Michael Dale Eisenbraun ,  Douglas Hanahan ,  David H. Kirn ,  Clare Lees ,  Prajit Limsirichai ,  Liliana Maruri Avidal

IPC分类号： A61K35/768 ,  C12N15/86 ,  A61K39/395 ,  C07K14/55 ,  C12N9/12 ,  A61P35/00

CPC分类号： A61K35/768 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/55 ,  C12N9/1211 ,  C12N15/86 ,  C12Y207/01021 ,  C12N2710/24132 ,  C12N2710/24143

摘要： The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.

公开(公告)号：US11684616B2

公开(公告)日：2023-06-27

申请号：US17246551

申请日：2021-04-30

申请人： PFIZER INC.

发明人： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K31/444 ,  A61K45/06

CPC分类号： A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

摘要： This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20230192690A1

公开(公告)日：2023-06-22

申请号：US18112156

申请日：2023-02-21

申请人： PFIZER INC.

发明人： Lei Zhang ,  Christopher Ryan Butler ,  Elizabeth Mary Beck ,  Michael Aaron Brodney ,  Matthew Frank Brown ,  Laura Ann McAllister ,  Erik Alphie LaChapelle ,  Adam Matthew Gilbert

IPC分类号： C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

CPC分类号： C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

摘要： The present invention provides, in part, compounds of Formula I:




or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

公开(公告)号：US20230174532A1

公开(公告)日：2023-06-08

申请号：US18162052

申请日：2023-01-31

申请人： Pfizer Inc.

发明人： Christopher Ryan BUTLER ,  Michelle Renee GARNSEY ,  Kevin Alexander OGILVIE ,  Jana POLIVKOVA ,  Matthew Forrest SAMMONS ,  Aaron Christopher SMITH ,  Qingyi Yang

IPC分类号： C07D471/20 ,  C07D519/00

CPC分类号： C07D471/20 ,  C07D519/00 ,  C07B2200/13

摘要： Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:




or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.